GC WellBeing Corporation
KKRX:23469011,230.00
KRW
+490.00
(+4.56%)
ISIN
KR7234690006
Return %
Stock
S&P 500
1Y
20.62
14.20
3Y
82.90
81.12
5Y
-1.92
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Hyeon Kim
- Full Time Employees
- 330
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Oct 14, 2019
- Website
- greencrosswb.com
- Similar Companies
- Business
- GC WellBeing Corporation is a South Korea-based biopharmaceutical and healthcare company primarily engaged in the development, manufacture, and commercialization of specialized therapeutic nutritional injections, dietary supplements, medical aesthetics, and contract development and manufacturing organization (CDMO) services. Founded in 2004 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates as an affiliate of GC Holdings (Green Cross Group). GC WellBeing Corporation structures its core operations across specialized healthcare segments, offering a comprehensive portfolio of medical and wellness solutions: therapeutic and nutritional injections, including human placenta extract injectables marketed under the flagship brand Laennec for hepatoprotection and fatigue recovery; high-dose vitamin infusions such as Megagreen; antioxidant injectables comprising thioctic acid, glutathione, and ascorbic acid formulations; multivitamin and amino acid intravenous solutions; and hyaluronic acid-based intra-articular viscosupplementation injections for joint pain management; dietary and health functional foods, featuring personalized nutrition therapy formulations marketed under the Dr. PNT brand; targeted probiotics; gastrointestinal and liver health supplements; and bone and joint wellness products; medical aesthetics and cosmeceuticals, consisting of placenta-derived functional skincare, topical therapeutics, and dermatological solutions; and CDMO services, providing aseptic liquid and lyophilized vial and ampoule fill-finish manufacturing from its automated, KGMP-compliant production facility in Eumseong, Chungcheongbuk-do. The company serves hospitals, specialized clinics, pharmacies, and consumer retail channels across South Korea, while exporting pharmaceutical and nutritional products to international markets across Asia, Latin America, and the Middle East. In recent corporate developments, GC WellBeing Corporation has advanced strategic business reorganizations to optimize its operational portfolio, streamlining select consumer healthcare operations to concentrate resources on high-margin ethical pharmaceutical injectables and specialized nutrition therapies. The company has expanded the clinical indications and global footprint of Laennec through clinical research in hepatic and musculoskeletal disorders, entered into strategic co-promotion and distribution agreements for aesthetic therapeutics, and scaled its injectable CDMO business through new manufacturing partnerships.